A detailed history of Ameritas Investment Partners, Inc. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 15,156 shares of RVMD stock, worth $656,103. This represents 0.02% of its overall portfolio holdings.

Number of Shares
15,156
Previous 14,928 1.53%
Holding current value
$656,103
Previous $579,000 18.48%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$36.92 - $47.94 $8,417 - $10,930
228 Added 1.53%
15,156 $686,000
Q2 2024

Aug 13, 2024

BUY
$30.14 - $40.68 $30,652 - $41,371
1,017 Added 7.31%
14,928 $579,000
Q1 2024

May 13, 2024

SELL
$26.56 - $33.55 $25,975 - $32,811
-978 Reduced 6.57%
13,911 $448,000
Q4 2023

Feb 14, 2024

BUY
$18.35 - $34.12 $88,318 - $164,219
4,813 Added 47.77%
14,889 $427,000
Q3 2023

Nov 13, 2023

BUY
$25.17 - $35.05 $42,814 - $59,620
1,701 Added 20.31%
10,076 $278,000
Q2 2023

Aug 11, 2023

BUY
$20.28 - $27.0 $32,184 - $42,849
1,587 Added 23.38%
8,375 $224,000
Q1 2023

May 10, 2023

BUY
$20.76 - $30.09 $19,722 - $28,585
950 Added 16.27%
6,788 $147,000
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $20,620 - $30,706
1,181 Added 25.36%
5,838 $115,000
Q2 2021

Aug 06, 2021

BUY
$29.0 - $47.44 $34,307 - $56,121
1,183 Added 34.05%
4,657 $148,000
Q1 2021

May 14, 2021

BUY
$37.21 - $54.43 $6,958 - $10,178
187 Added 5.69%
3,474 $159,000
Q3 2020

Nov 13, 2020

BUY
$22.61 - $34.8 $46,734 - $71,931
2,067 Added 169.43%
3,287 $114,000
Q1 2020

May 13, 2020

BUY
$20.0 - $34.08 $24,400 - $41,577
1,220 New
1,220 $27,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.